Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

Vrieling, Alina ; Hein, Rebecca ; Abbas, Sascha ; Schneeweiß, Andreas ; Flesch-Janys, Dieter ; Chang-Claude, Jenny

In: Breast Cancer Research, 13 (2011), Nr. R74. pp. 1-9. ISSN 1465-542X

[img]
Preview
PDF, English
Download (360kB) | Lizenz: Creative Commons LizenzvertragSerum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study by Vrieling, Alina ; Hein, Rebecca ; Abbas, Sascha ; Schneeweiß, Andreas ; Flesch-Janys, Dieter ; Chang-Claude, Jenny underlies the terms of Creative Commons Attribution 3.0 Germany

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Introduction: Vitamin D has been postulated to be involved in cancer prognosis. Thus far, only two studies reported on its association with recurrence and survival after breast cancer diagnosis yielding inconsistent results. Therefore, the aim of our study was to assess the effect of post-diagnostic serum 25-hydroxyvitamin D [25(OH)D] concentrations on overall survival and distant disease-free survival. Methods: We conducted a prospective cohort study in Germany including 1,295 incident postmenopausal breast cancer patients aged 50-74 years. Patients were diagnosed between 2002 and 2005 and median follow-up was 5.8 years. Cox proportional hazards models were stratified by age at diagnosis and season of blood collection and adjusted for other prognostic factors. Fractional polynomials were used to assess the true dose-response relation for 25(OH)D. Results: Lower concentrations of 25(OH)D were linearly associated with higher risk of death (hazard ratio (HR) = 1.08 per 10 nmol/L decrement; 95% confidence interval (CI), 1.00 to 1.17) and significantly higher risk of distant recurrence (HR = 1.14 per 10 nmol/L decrement; 95%CI, 1.05 to 1.24). Compared with the highest tertile (≥ 55 nmol/L), patients within the lowest tertile (< 35 nmol/L) of 25(OH)D had a HR for overall survival of 1.55 (95%CI, 1.00 to 2.39) and a HR for distant disease-free survival of 2.09 (95%CI, 1.29 to 3.41). In addition, the association with overall survival was found to be statistically significant only for 25(OH)D levels of blood samples collected before start of chemotherapy but not for those of samples taken after start of chemotherapy (P for interaction = 0.06). Conclusions: In conclusion, lower serum 25(OH)D concentrations may be associated with poorer overall survival and distant disease-free survival in postmenopausal breast cancer patients.

Item Type: Article
Journal or Publication Title: Breast Cancer Research
Volume: 13
Number: R74
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 27 Jan 2017 09:39
Date: 2011
ISSN: 1465-542X
Page Range: pp. 1-9
Faculties / Institutes: Service facilities > German Cancer Research Center (DKFZ)
Medizinische Fakultät Heidelberg > Universitäts-Frauenklinik
Subjects: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative